Stuart leads the development of investigational medicines for SLD at the pharmaceutical company GSK. His role has strategic oversight of several large late - phase clinical trials in MASH and ALD, as well as product safety and manufacturing, translational, biology and epidemiology studies.

He joined GSK R&D in 2014. His roles in Discovery Research, Clinical Development and Medical Affairs have included leadership in fibrosis, cholestatic liver disease and chronic hepatitis B in addition to SLD. He is fortunate to have held different leadership roles in the whole journey of a single investigational medicine from the first identification of the disease - target pairing through to regulatory approval.

Stuart grew up in Belfast, Northern Ireland and qualified in Physiology from Cambridge, Medicine from Oxford, and a PhD from Newcastle University, where his thesis explored genetic and epigenetic determinants of macrophage function in SLD. His specialty training was in Internal Medicine, Gastroenterology and Hepatology in Nottingham, London and Newcastle upon Tyne. He was a senior academic Hepatologist in Newcastle before transitioning to industry research.

In addition to his core accountabilities, Stuart chairs GSK’s Hepatic Safety Panel and is responsible for the practice licenses for GSK’s UK - registered physicians. He is an honorary consultant hepatologist at Cambridge University Hospitals where he sees patients on Friday mornings.